Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesKrystal Biotech Inc

Krystal Biotech Inc

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
310.84 USD 0.00(0%)
Last update at 2026-11-04T21:00:00Z
VOLUME
386716
Market Cap
10158.02M
P/E
43.39

Momentum Score

…

Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, manufactures, and commercializes genetic medicines to treat diseases with high unmet medical needs in the United States. The company commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). It also develops KB803 for ocular complications of dystrophic epidermolysis bullosa; KB801 for neurotrophic keratitis; KB407, which is in Phase 1 clinical trials for treating cystic fibrosis; KB111 for Hailey-Hailey disease; KB707 for solid tumors; KB304 for dynamic wrinkles; KB707 that is in Phase 1/2 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
301.80
Low
314.75
High
52 Week Price Range
155.20
Low
382.54
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Krystal Biotech develops topical gene therapies for rare dermatologic conditions using a proprietary delivery platform and a pipeline focused on inherited skin disorders and wound healing. Long-term growth drivers include commercializing lead candidates, broadening indications, leveraging the platform for additional skin diseases and forming strategic partnerships, which may benefit from high unmet medical need in small, concentrated patient populations.
The principal risks are clinical and regulatory setbacks, limited commercial traction in small markets, potential competition and the need for additional capital to support development and commercialization.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
310.84
Dividend Yield
-
Revenue TTM
440.48M
Revenue Per Share
15.08
Gross Profit TTM
416.87M
Debt / Equity
0.01
ROE
20.12%
Net Debt
-486.96M
ROCE
15.39%
Diluted EPS TTM
7.91

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax 189.47M 95.36M 12.90M -139.97M -69.57M
Net income 204.83M 89.16M 10.93M -139.97M -69.57M
Selling general administrative 146.74M 113.69M 98.40M 77.73M 40.39M
Gross profit 360.36M 270.45M 47.60M - -
Reconciled depreciation 6.55M 6.71M 5.01M 4.05M 2.77M
Ebit 189.47M 103.19M -97.23M -145.20M -68.28M
Ebitda 196.02M 109.91M -91.32M -110.92M -65.31M
Depreciation and amortization 6.55M 6.71M 5.91M 34.28M 2.97M
Operating income 161.29M 65.69M -109.73M -145.20M -68.28M
Other operating expenses 227.84M 224.82M 160.43M 120.20M 68.28M
Interest expense - - 0.00M 5.22M 1.49M
Tax provision -15.36M 6.20M 1.97M - -
Interest income 28.18M 29.66M 22.62M 5.22M 0.20M
Net interest income 28.18M 29.66M 22.62M 5.22M -1.29M
Income tax expense -15.36M 6.20M 1.97M 19.78M 1.49M
Total revenue 389.13M 290.51M 50.70M 0.00M 0.00M
Total operating expenses 199.06M 204.76M 157.33M 120.20M 68.28M
Cost of revenue 28.77M 20.06M 3.09M - -
Total other income expense net 28.18M 29.66M 122.62M 5.22M -1.29M
Net income from continuing ops 204.83M 89.16M 10.93M -139.97M -69.57M
Net income applicable to common shares - - - -139.97M -69.57M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 1333.79M 1055.84M 818.36M 558.45M 626.29M
Other current assets 28.91M 13.27M 6.71M 4.61M 4.17M
Total liab 114.23M 109.46M 39.71M 36.22M 32.72M
Total stockholder equity 1219.56M 946.38M 778.64M 522.23M 593.58M
Other current liab 97.93M 91.50M 27.49M 23.30M 0.09M
Capital stock 0.00M 0.00M 0.00M 0.00M 0.00M
Retained earnings 24.16M -180.67M -269.83M -280.76M -140.78M
Other assets - - - 0.32M 0.07M
Cash 496.30M 344.87M 358.33M 161.90M 341.25M
Total current liabilities 102.94M 102.00M 33.09M 28.85M 25.74M
Current deferred revenue - - 0.00M - 16.21M
Net debt -486.96M -337.60M -350.23M -152.97M -333.22M
Short term debt 1.77M 1.22M 1.47M 1.56M 1.04M
Short long term debt total 9.34M 7.26M 8.09M 8.93M 8.02M
Other stockholder equity 1194.26M 1127.24M 1047.83M 803.72M 734.52M
Property plant equipment - - - 169.73M 119.58M
Total current assets 1024.60M 742.04M 587.91M 383.78M 442.27M
Long term investments 128.07M 152.11M 61.95M 4.62M 64.37M
Net tangible assets - - - 522.23M 593.58M
Short term investments 331.49M 252.65M 173.85M 217.27M 96.85M
Net receivables 127.42M 104.75M 42.04M - -
Inventory 40.48M 26.51M 6.99M - -
Accounts payable 3.24M 4.99M 4.13M 3.98M 8.40M
Accumulated other comprehensive income 1.14M -0.19M 0.64M -0.73M -0.16M
Retained earnings total equity - - - - -140.78M
Non currrent assets other 0.29M 0.23M 0.26M 0.32M 0.07M
Non current assets total 309.19M 313.79M 230.45M 174.67M 184.03M
Capital lease obligations 9.34M 7.26M 8.09M 8.93M 8.02M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments -46.90M -163.44M 82.64M -114.08M -158.43M
Change to liabilities - - - -1.25M 0.71M
Total cashflows from investing activities -58.42M -163.44M 82.64M -114.08M -226.77M
Total cash from financing activities 8.71M 27.01M 202.75M 35.35M 347.69M
Change to operating activities - - - 4.07M 1.34M
Net income 204.83M 89.16M 10.93M -139.97M -69.57M
Change in cash 151.44M -13.46M 196.43M -179.35M 72.98M
Begin period cash flow 344.87M 358.33M 161.90M 341.25M 268.27M
End period cash flow 496.30M 344.87M 358.33M 161.90M 341.25M
Total cash from operating activities 200.87M 123.42M -88.80M -100.57M -47.94M
Issuance of capital stock 0.00M 0.00M 203.50M 36.00M 355.64M
Depreciation 6.55M 6.71M 5.01M 4.05M 2.77M
Other cashflows from investing activities - - 100.00M - -
Change to inventory -6.29M -11.91M -4.47M - -
Change to account receivables -22.12M -62.71M -42.04M - -
Sale purchase of stock - - - - 355.64M
Other cashflows from financing activities -13.96M -5.39M -0.75M -0.65M -7.96M
Change to netincome - - - 32.54M 16.81M
Capital expenditures 11.95M 4.24M 11.80M 52.98M 68.34M
Cash flows other operating - - - - -1.08M
Cash and cash equivalents changes - - - - 72.98M
Change in working capital -36.42M -14.46M -37.88M 2.81M 2.05M
Stock based compensation 54.51M 49.13M 39.93M 33.23M 15.32M
Other non cash items -5.77M -7.12M -106.79M -0.69M 1.49M
Free cash flow 188.91M 119.18M -100.60M -153.55M -116.27M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
KRYS
Krystal Biotech Inc		 -
-%		 310.84 43.39 46.73 23.06 7.40 20.94 45.12
NVO
Novo Nordisk A/S		 1.99
4.95%		 42.18 41.58 31.15 2.13 32.99 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 18.28
3.44%		 549.04 30.22 24.27 10.36 6.50 9.99 24.66
REGN
Regeneron Pharmaceuticals Inc		 -41.91
4.31%		 931.45 29.07 20.12 7.57 3.82 6.95 19.42
ARGNF
argenx SE		 -
-%		 900.30 45.77 31.25 13.84 7.12 11.38 36.06

Profile*

Krystal Biotech Inc

Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, manufactures, and commercializes genetic medicines to treat diseases with high unmet medical needs in the United States. The company commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). It also develops KB803 for ocular complications of dystrophic epidermolysis bullosa; KB801 for neurotrophic keratitis; KB407, which is in Phase 1 clinical trials for treating cystic fibrosis; KB111 for Hailey-Hailey disease; KB707 for solid tumors; KB304 for dynamic wrinkles; KB707 that is in Phase 1/2 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.

2100 Wharton Street, Pittsburgh, PA, United States, 15203

412 586 5830

https://www.krystalbio.com

295

Name Title Year Born
Mr. Krish S. Krishnan M.B.A., M.S. Founder, Chairman, Pres & CEO 1965
Ms. Suma M. Krishnan Founder, COO, Pres of R&D and Director 1965
Ms. Kathryn A. Romano Exec. VP & Chief Accounting Officer 1981
Dr. Andreas C. Orth Exec. VP & Chief Commercial Officer 1970
Ms. Gloria Lin Accounting Mang. NA
Mr. Ram Kamineni Sr. VP of CMC & Technical Operations NA
Ms. Meg Dodge VP of Investor Relations & Corp. Communications NA
Mr. David Glynn Gen. Counsel, Commercial & Compliance NA
Mr. John Karakkal VP of North American Sales & Marketing NA
Ms. Katherine Tuminello HR & Office Mang. NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

PRL
CAD 30.50
+15.05%
DSV
CAD 11.02
+14.55%
USA
CAD 4.29
+13.19%
NUAG
CAD 7.70
+12.90%
GMIN
CAD 43.79
+12.86%
DRUG
CAD 26.11
-29.58%
HUT
CAD 68.98
-22.41%
UCU
CAD 2.09
-14.34%
VET
CAD 14.87
-14.29%
PHX
CAD 10.96
-13.56%

Equity Sectors*

  • Basic Materials

    +5.46%

  • Communication Services

    +3.38%

  • Consumer Cyclical

    +3.11%

  • Consumer Defensive

    +1.35%

  • Energy

    -4.79%

  • Financial Services

    +2.66%

  • Healthcare

    -0.72%

  • Industrials

    -0.11%

  • Real Estate

    +1.84%

  • Technology

    +1.05%

  • Utilities

    +0.39%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…